Loading...

Vical

DB:VCC1
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
VCC1
DB
$25M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The last earnings update was 54 days ago. More info.


Add to Portfolio Compare Print
VCC1 Share Price and Events
7 Day Returns
-0.1%
DB:VCC1
-0.1%
DE Biotechs
1%
DE Market
1 Year Returns
-16.9%
DB:VCC1
-7.4%
DE Biotechs
-5.6%
DE Market
VCC1 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Vical (VCC1) -0.1% -5.2% 28.2% -16.9% -68% -87.9%
DE Biotechs -0.1% 6% -6.7% -7.4% 53.2% 11.6%
DE Market 1% 6.1% 8.4% -5.6% 10.9% 13.8%
1 Year Return vs Industry and Market
  • VCC1 underperformed the Biotechs industry which returned -7.4% over the past year.
  • VCC1 underperformed the Market in Germany which returned -5.6% over the past year.
Price Volatility
VCC1
Industry
5yr Volatility vs Market
Related Companies

VCC1 Value

 Is Vical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Vical. This is due to cash flow or dividend data being unavailable. The share price is €1.005.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Vical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Vical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:VCC1 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.74
NasdaqCM:VICL Share Price ** NasdaqCM (2019-04-24) in USD $1.16
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.73x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.72x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Vical.

DB:VCC1 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:VICL Share Price ÷ EPS (both in USD)

= 1.16 ÷ -0.74

-1.56x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vical is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Vical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Vical's expected growth come at a high price?
Raw Data
DB:VCC1 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.56x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 1 Analysts
Not available
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 269 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Vical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Vical's assets?
Raw Data
DB:VCC1 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $2.24
NasdaqCM:VICL Share Price * NasdaqCM (2019-04-24) in USD $1.16
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.72x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:VCC1 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:VICL Share Price ÷ Book Value per Share (both in USD)

= 1.16 ÷ 2.24

0.52x

* Primary Listing of Vical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Vical is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Vical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Vical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

VCC1 Future Performance

 How is Vical expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
47.6%
Expected Biotechs industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Vical expected to grow at an attractive rate?
  • Unable to compare Vical's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Vical's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare Vical's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:VCC1 Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.6%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:VCC1 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:VCC1 Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2019-12-31 0 -7 1
DB:VCC1 Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 2 -14 -16
2018-09-30 5 -14 -16
2018-06-30 9 -13 -18
2018-03-31 11 -11 -16
2017-12-31 14 -9 -13
2017-09-30 13 -9 -12
2017-06-30 12 -9 -11
2017-03-31 13 -8 -9
2016-12-31 15 -8 -9
2016-09-30 18 -8 -9
2016-06-30 21 -5 -6
2016-03-31 21 -6 -8

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Vical is high growth as no earnings estimate data is available.
  • Unable to determine if Vical is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:VCC1 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below

All data from Vical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VCC1 Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2019-12-31 -0.34 -0.34 -0.34 1.00
DB:VCC1 Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.74
2018-09-30 -0.79
2018-06-30 -0.98
2018-03-31 -1.05
2017-12-31 -1.01
2017-09-30 -1.07
2017-06-30 -1.04
2017-03-31 -0.89
2016-12-31 -0.90
2016-09-30 -0.90
2016-06-30 -0.69
2016-03-31 -0.85

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Vical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Vical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Vical has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

VCC1 Past Performance

  How has Vical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Vical's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Vical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Vical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Vical's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Vical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Vical Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:VCC1 Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 1.62 -16.25 6.19
2018-09-30 5.45 -16.38 6.27
2018-06-30 8.64 -17.95 6.50
2018-03-31 11.33 -16.41 6.83
2017-12-31 13.82 -12.96 6.34
2017-09-30 13.03 -12.00 6.47
2017-06-30 12.43 -11.44 6.45
2017-03-31 13.13 -9.37 6.78
2016-12-31 14.53 -8.97 7.06
2016-09-30 18.18 -8.56 7.43
2016-06-30 20.56 -6.33 7.72
2016-03-31 20.61 -7.84 7.93
2015-12-31 20.95 -9.24 8.37
2015-09-30 18.96 -11.52 8.65
2015-06-30 17.39 -15.58 9.10
2015-03-31 17.71 -16.86 9.51
2014-12-31 15.22 -16.49 9.55
2014-09-30 13.54 -14.05 8.77
2014-06-30 11.64 -19.57 9.13
2014-03-31 8.59 -25.41 10.07
2013-12-31 7.72 -31.24 11.31
2013-09-30 6.89 -36.60 12.38
2013-06-30 7.52 -34.44 12.08
2013-03-31 7.63 -32.43 11.38
2012-12-31 17.52 -22.90 10.56
2012-09-30 17.13 -21.96 13.24
2012-06-30 41.58 2.19 13.19

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Vical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Vical has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Vical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Vical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Vical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

VCC1 Health

 How is Vical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Vical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Vical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Vical has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Vical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Vical has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Vical Company Filings, last reported 3 months ago.

DB:VCC1 Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 48.76 0.00 48.07
2018-09-30 52.10 0.00 50.37
2018-06-30 53.59 0.00 51.90
2018-03-31 58.22 0.00 55.92
2017-12-31 63.58 0.00 60.50
2017-09-30 37.73 0.00 32.84
2017-06-30 39.80 0.00 31.86
2017-03-31 42.59 0.00 33.78
2016-12-31 45.14 0.00 35.62
2016-09-30 47.86 0.00 37.45
2016-06-30 42.44 0.00 32.98
2016-03-31 43.38 0.00 34.87
2015-12-31 45.39 0.00 36.71
2015-09-30 47.45 0.00 38.61
2015-06-30 47.22 0.00 38.56
2015-03-31 49.51 0.00 41.05
2014-12-31 51.92 0.00 43.97
2014-09-30 55.66 0.00 46.53
2014-06-30 56.72 0.00 46.42
2014-03-31 58.75 0.00 47.85
2013-12-31 61.41 0.00 50.38
2013-09-30 62.89 0.00 55.85
2013-06-30 71.74 0.00 64.44
2013-03-31 81.15 0.00 72.38
2012-12-31 89.09 0.00 80.80
2012-09-30 95.99 0.00 86.89
2012-06-30 102.83 0.00 91.82
  • Vical has no debt.
  • Vical has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Vical has sufficient cash runway for more than 3 years based on current free cash flow.
  • Vical has sufficient cash runway for 2.7 years if free cash flow continues to grow at historical rates of 28.6% each year.
X
Financial health checks
We assess Vical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Vical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

VCC1 Dividends

 What is Vical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Vical dividends.
If you bought €2,000 of Vical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Vical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Vical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:VCC1 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 1 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:VCC1 Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Vical has not reported any payouts.
  • Unable to verify if Vical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Vical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Vical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Vical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Vical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Vical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

VCC1 Management

 What is the CEO of Vical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Vijay Samant
COMPENSATION $1,075,646
AGE 65
TENURE AS CEO 18.4 years
CEO Bio

Mr. Vijay B. Samant has been the Chief Executive Officer and President of Vical Incorporation since November 2000. Mr. Samant joined Vical Inc. in November 2000. He served as Acting Chief Financial Officer of Vical Incorporated from April 12, 2013 to May 25, 2017. He has over 23 years of U.S. and International Pharmaceuticals experience in the areas of Sales, Marketing, Operations and Business Development. Previously, Mr. Samant held various positions at Merck & Co. Inc. from 1977 to 2000. From 1998 to 2000, he served as the Chief Operating Officer of the Merck Vaccine Division. He served as Chief Executive Officer of the Merck Vaccine Division. From 1990 to 1998, he served in the Merck Manufacturing Division as Vice President of Vaccine Operations, Vice President of Business Affairs and Executive Director of Materials Management. From 1977 to 1990, Mr. Samant held a variety of positions of increasing responsibility in manufacturing, process engineering, production planning and control, business development and loss prevention in several Merck operating divisions. He has been a Non-Executive Director of AmpliPhi Biosciences Corporation since November 2015. He has been a Director of Vical Incorporated since November 2000. Mr. Samant was a member of the Board of Trustees for the International Vaccine Institute (IVI, Seoul, Korea) since 2008 to 2012 and a member of the Board of Trustees for the National Foundation for Infectious Diseases (NFID, Bethesda, MD) since 2003 to 2012. He served as a Director of Raptor Pharmaceuticals Corp, from April 13, 2011 to July 28, 2014 and a Director of the Aeras Global TB Vaccine Foundation from 2001 to 2010. He served as a Director of BioMarin Pharmaceutical Inc. from June 15, 2002 to May 4, 2004. Mr. Samant also serves on the Project Management Subcommittee of the International AIDS Vaccine Initiative. Mr. Samant holds an MBA from the Sloan School of Management at the Massachusetts Institute of Technology, an MS in Chemical Engineering from Columbia University and a BS in Chemical Engineering from the University of Bombay, University Department of Chemical Technology, India.

CEO Compensation
  • Vijay's compensation has increased whilst company is loss making.
  • Vijay's remuneration is higher than average for companies of similar size in Germany.
Management Team

Vijay Samant

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
65
TENURE
18.4 yrs

Tony Ramos

TITLE
VP, CFO & Chief Accounting Officer
COMPENSATION
$433K
AGE
51
TENURE
1.9 yrs
Board of Directors Tenure

Average tenure and age of the Vical board of directors in years:

11.8
Average Tenure
67
Average Age
  • The average tenure for the Vical board of directors is over 10 years, this suggests they are a seasoned and experienced board.
Board of Directors

R. Douglas

TITLE
Chairman of the Board
COMPENSATION
$87K
AGE
83

Vijay Samant

TITLE
CEO, President & Director
COMPENSATION
$1M
AGE
65
TENURE
18.4 yrs

Gary Lyons

TITLE
Director
COMPENSATION
$68K
AGE
67
TENURE
22.1 yrs

Robert Merton

TITLE
Director
COMPENSATION
$76K
AGE
73
TENURE
17.1 yrs

Greg Morrow

TITLE
Director
COMPENSATION
$73K
AGE
66
TENURE
6.5 yrs

Richard Beleson

TITLE
Director
COMPENSATION
$58K
AGE
64
TENURE
5.9 yrs

Tom Shenk

TITLE
Director
COMPENSATION
$58K
AGE
71
TENURE
3.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
14. Jan 19 Sell Armistice Capital LLC Company 10. Jan 19 10. Jan 19 -2,190,500 €0.77 €-1,677,012
02. Jul 18 Buy Armistice Capital LLC Company 28. Jun 18 28. Jun 18 1,276,591 €1.04 €1,327,987
27. Jun 18 Buy Armistice Capital LLC Company 25. Jun 18 27. Jun 18 51,805 €1.09 €55,324
22. Jun 18 Buy Armistice Capital LLC Company 20. Jun 18 22. Jun 18 18,362 €1.09 €19,821
18. Jun 18 Buy Armistice Capital LLC Company 18. Jun 18 18. Jun 18 13,742 €1.04 €14,232
18. Jun 18 Buy Armistice Capital LLC Company 14. Jun 18 14. Jun 18 29,103 €0.99 €28,778
13. Jun 18 Buy Armistice Capital LLC Company 11. Jun 18 13. Jun 18 670,897 €1.04 €661,806
X
Management checks
We assess Vical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Vical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

VCC1 News

Simply Wall St News

VCC1 Company Info

Description

Vical Incorporated researches and develops biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company was founded in 1987 and is headquartered in San Diego, California.

Details
Name: Vical Incorporated
VCC1
Exchange: DB
Founded: 1987
$22,428,502
21,827,695
Website: http://www.vical.com
Address: Vical Incorporated
10390 Pacific Center Court,
San Diego,
California, 92121,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM VICL Common Stock Nasdaq Capital Market US USD 10. Mar 1993
DB VCC1 Common Stock Deutsche Boerse AG DE EUR 10. Mar 1993
Number of employees
Current staff
Staff numbers
30
Vical employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/24 21:53
End of day share price update: 2019/04/24 00:00
Last estimates confirmation: 2019/02/25
Last earnings filing: 2019/03/01
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.